In March 2025, the World Health Organization (WHO) announced the death of a 4-year-old child from Ebola, marking a concerning resurgence of the deadly virus. The child had been hospitalized at Mulago National Referral Hospital and tragically passed away on February 25.
This latest death is a setback for health officials, who had hoped for a quick end to the Ebola outbreak that began in late January 2025. Earlier, a male nurse was the first confirmed fatality in the outbreak.
The eight patients who had been contacts of the deceased male nurse were treated successfully. This led to health officials believing the end of the outbreak. However, the second death has raised new concerns.
Ebola in Uganda is the latest trend of viral hemorrhagic fever outbreaks in the East African region. This deadly virus is spread by contact with the bodily fluids of an infected person or contaminated materials. Common symptoms include vomiting, fever, diarrhea, muscle pain, and bleeding.
The resurgence of Ebola in nations like Uganda will likely put the Ebola vaccine industry into the limelight. According to Coherent Market Insights (CMI), demand for Ebola vaccines is projected to rise significantly as nations look to eradicate Ebola spread and mortality rate.
Currently, there are no approved vaccines for the Sudan strain of Ebola virus affecting Uganda. This is directing investments in new vaccine research and development, clinical trials, and approvals. For instance, in February 2025, Uganda’s Ministry of Health along with the WHO and other partners launched a new clinical trial to assess the safety and efficacy of a candidate vaccine targeting the Sudan strain.
The WHO has already given around about US$ 3 million to support its Ebola response in Uganda. According to WHO, around 20,000 travelers are daily screened for Ebola at Uganda’s different border crossing points. However, the United States’ latest decision to terminate 60% of USAID’s foreign aid contracts has raised concerns about adequate funding.
Organizations like Baylor College of Medicine Children’s Foundation have stopped their support for local health authorities in screening traveling passengers due to termination of their contracts with USAID.
Despite these challenges, pharmaceutical companies are expected to accelerate their efforts in developing vaccines for the Sudan strain of the Ebola virus. This will play a key role in boosting overall growth of the global Ebola vaccine industry during the forecast period.
“The new Sudan strain is creating new challenges for governments and pharmaceutical industries in combating the deadly Ebola. As a result, more investments and efforts are being directed towards developing novel Ebola vaccines. This will play a key role in fostering the industry’s growth in the coming years,” says a senior analyst at CMI.”
Outbreak of new Ebola strains is set to create lucrative revenue-generation opportunities for pharmaceutical and biotechnology companies. Top companies in the Ebola vaccine industry are expected to heavily invest in research and development to create new vaccines with better safety and efficacy in tackling various Ebola strains. As a result, robust growth is on the cards for the global Ebola vaccine industry.